S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
Log in

Tyme Technologies Stock Price, Forecast & Analysis (NASDAQ:TYME)

$1.19
-0.01 (-0.83 %)
(As of 11/11/2019 04:00 PM ET)
Today's Range
$1.16
Now: $1.19
$1.20
50-Day Range
$1.19
MA: $1.39
$1.73
52-Week Range
$0.92
Now: $1.19
$4.64
Volume195,387 shs
Average Volume644,017 shs
Market Capitalization$133.22 million
P/E RatioN/A
Dividend YieldN/A
Beta0.39
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TYME
CUSIPN/A
Phone212-461-2315

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.07 per share

Profitability

Net Income$-32,980,000.00

Miscellaneous

Employees11
Market Cap$133.22 million
Next Earnings Date2/10/2020 (Estimated)
OptionableOptionable

Receive TYME News and Ratings via Email

Sign-up to receive the latest news and ratings for TYME and its competitors with MarketBeat's FREE daily newsletter.


Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

How were Tyme Technologies' earnings last quarter?

Tyme Technologies Inc (NASDAQ:TYME) posted its quarterly earnings results on Monday, November, 4th. The company reported ($0.04) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.06) by $0.02. View Tyme Technologies' Earnings History.

When is Tyme Technologies' next earnings date?

Tyme Technologies is scheduled to release their next quarterly earnings announcement on Monday, February 10th 2020. View Earnings Estimates for Tyme Technologies.

What price target have analysts set for TYME?

1 equities research analysts have issued 1 year price objectives for Tyme Technologies' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Tyme Technologies' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 740.3% from the stock's current price. View Analyst Price Targets for Tyme Technologies.

What is the consensus analysts' recommendation for Tyme Technologies?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tyme Technologies.

What are Wall Street analysts saying about Tyme Technologies stock?

Here are some recent quotes from research analysts about Tyme Technologies stock:
  • 1. According to Zacks Investment Research, "Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body's immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York. " (11/8/2019)
  • 2. HC Wainwright analysts commented, "We maintain our Buy rating of TYME and our 12-month price target of $9.50 per share. We derive our price target based on a net present value analysis of projected SM-88 revenues through FY2030, assuming a 12% discount rate and 2% terminal growth rate." (8/12/2019)

Has Tyme Technologies been receiving favorable news coverage?

Media coverage about TYME stock has trended very negative on Monday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tyme Technologies earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Tyme Technologies.

Are investors shorting Tyme Technologies?

Tyme Technologies saw a increase in short interest in October. As of October 15th, there was short interest totalling 8,200,000 shares, an increase of 6.6% from the September 15th total of 7,690,000 shares. Based on an average trading volume of 454,900 shares, the days-to-cover ratio is currently 18.0 days. Approximately 16.2% of the shares of the company are short sold. View Tyme Technologies' Current Options Chain.

Who are some of Tyme Technologies' key competitors?

What other stocks do shareholders of Tyme Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Bausch Health Companies (BHC), Karyopharm Therapeutics (KPTI), OpGen (OPGN), Rigel Pharmaceuticals (RIGL), New Age Beverages (NBEV), Aurora Cannabis (ACB), Allena Pharmaceuticals (ALNA), Novavax (NVAX), NVIDIA (NVDA) and Viking Therapeutics (VKTX).

Who are Tyme Technologies' key executives?

Tyme Technologies' management team includes the folowing people:
  • Mr. Steven E. Hoffman, Co-Founder, Chairman, CEO & Chief Science Officer (Age 56)
  • Mr. Ben R. Taylor, Pres & CFO (Age 42)
  • Mr. Michael S. Demurjian, Co-Founder, Exec. VP, COO & Director (Age 52)
  • Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 55)
  • Dr. Giuseppe Del Priore, Chief Medical Officer (Age 57)

Who are Tyme Technologies' major shareholders?

Tyme Technologies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Perkins Capital Management Inc. (0.13%). Company insiders that own Tyme Technologies stock include Barbara Galaini, David Carberry, Douglas A Michels, Michael Demurjian, Michele Ilene Korfin and Steve Hoffman. View Institutional Ownership Trends for Tyme Technologies.

Which institutional investors are buying Tyme Technologies stock?

TYME stock was acquired by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. Company insiders that have bought Tyme Technologies stock in the last two years include Barbara Galaini, David Carberry, Douglas A Michels, Michele Ilene Korfin and Steve Hoffman. View Insider Buying and Selling for Tyme Technologies.

How do I buy shares of Tyme Technologies?

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $1.19.

How big of a company is Tyme Technologies?

Tyme Technologies has a market capitalization of $133.22 million. The company earns $-32,980,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Tyme Technologies employs 11 workers across the globe.View Additional Information About Tyme Technologies.

What is Tyme Technologies' official website?

The official website for Tyme Technologies is http://www.tymeinc.com/.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]


MarketBeat Community Rating for Tyme Technologies (NASDAQ TYME)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  331
MarketBeat's community ratings are surveys of what our community members think about Tyme Technologies and other stocks. Vote "Outperform" if you believe TYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/11/2019 by MarketBeat.com Staff

Featured Article: What is a blue-chip stock?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel